Literature DB >> 31873848

Biochemical diagnosis in prolactinomas: some caveats.

Stephan Petersenn1.   

Abstract

Prolactinomas are the most frequently seen pituitary adenomas in clinical practice. A correct biochemical diagnosis of hyperprolactinemia is a prerequisite for further investigation but may be hampered by analytical difficulties as well as a large number of potentially overlapping conditions associated with increased prolactin levels. Suspicion should rise in patients whose symptoms and biochemical results do not match. Assay problems, macroprolactinemia, and high-dose hook effect are discussed as possible reasons for false positive or false negative prolactin levels. Physiological and pathological causes of hyperprolactinemia and their implications for interpreting prolactin results are reviewed.

Entities:  

Keywords:  Chronic kidney disease; High-dose hook effect; Hyperprolactinemia; Hypothyroidism; Liver disease; Macroprolactinemia; Pregnancy

Mesh:

Substances:

Year:  2020        PMID: 31873848     DOI: 10.1007/s11102-019-01024-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  53 in total

1.  Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A(1c), IgA, prolactin, and free testosterone in healthy women.

Authors:  A H Garde; A M Hansen; L T Skovgaard; J M Christensen
Journal:  Clin Chem       Date:  2000-04       Impact factor: 8.327

2.  The 'hook effect' on serum prolactin estimation in a patient with macroprolactinoma.

Authors:  A G Unnikrishnan; S Rajaratnam; M S Seshadri; A S Kanagasapabathy; D C Stephen
Journal:  Neurol India       Date:  2001-03       Impact factor: 2.117

Review 3.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Authors:  Shlomo Melmed; Felipe F Casanueva; Andrew R Hoffman; David L Kleinberg; Victor M Montori; Janet A Schlechte; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2011-02       Impact factor: 5.958

Review 4.  The hypothalamic-pituitary axis in men and women with chronic kidney disease.

Authors:  Jean L Holley
Journal:  Adv Chronic Kidney Dis       Date:  2004-10       Impact factor: 3.620

5.  Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia.

Authors:  Martin Overgaard; Susanne Møller Pedersen
Journal:  Clin Chem Lab Med       Date:  2017-10-26       Impact factor: 3.694

6.  Hyperprolactinaemia and luteal insufficiency.

Authors:  M Seppälä; T Ranta; E Hirvonen
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

7.  Tri-iodothyronine and phenytoin reduce prolactin messenger RNA levels in cultured rat pituitary cells.

Authors:  J R Davis; T C Lynam; J A Franklyn; K Docherty; M C Sheppard
Journal:  J Endocrinol       Date:  1986-06       Impact factor: 4.286

Review 8.  Macroprolactinemia: a new cause of hyperprolactinemia.

Authors:  Naoki Hattori
Journal:  J Pharmacol Sci       Date:  2003-07       Impact factor: 3.337

9.  Hyperprolactinemia and contraception: a prospective study.

Authors:  A A Luciano; B M Sherman; F K Chapler; K S Hauser; R B Wallace
Journal:  Obstet Gynecol       Date:  1985-04       Impact factor: 7.661

10.  Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms.

Authors:  Luisa Beltran; Michael N Fahie-Wilson; T Joseph McKenna; Lucille Kavanagh; Thomas P Smith
Journal:  Clin Chem       Date:  2008-08-21       Impact factor: 8.327

View more
  5 in total

1.  Diagnosis and management of prolactinomas: current challenges.

Authors:  Stephan Petersenn; Andrea Giustina
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

2.  Hypeprolactinemia: still an insidious diagnosis.

Authors:  Ludovica Aliberti; Irene Gagliardi; Romolo M Dorizzi; Stefano Pizzicotti; Marta Bondanelli; Maria Chiara Zatelli; Maria Rosaria Ambrosio
Journal:  Endocrine       Date:  2020-09-19       Impact factor: 3.633

3.  Multiple Endocrine Neoplasia Type 1 with Functional Parathyroid Cysts.

Authors:  Nobuyuki Koyama; Terumasa Nagase; Masahiko Kure; Tomotada Odaka; Koichiro Kogure; Yukihisa Takeda; Tomoya Ishii; Kenichiro Narisawa; Tomoyuki Fujita; Minoru Fujimori; Yoshiya Katsura
Journal:  Intern Med       Date:  2021-10-12       Impact factor: 1.282

Review 4.  Treatment of Prolactinoma.

Authors:  Warrick J Inder; Christina Jang
Journal:  Medicina (Kaunas)       Date:  2022-08-13       Impact factor: 2.948

5.  Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas.

Authors:  Nicholas A Tritos; Pouneh K Fazeli; Ann McCormack; Susana M Mallea-Gil; Maria M Pineyro; Mirjam Christ-Crain; Stefano Frara; Artak Labadzhyan; Adriana G Ioachimescu; Ilan Shimon; Yutaka Takahashi; Mark Gurnell; Maria Fleseriu
Journal:  Pituitary       Date:  2021-07-20       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.